CD8A and non-small cell lung carcinoma: In 2015, Hu et al. [28] reported that compared with chemotherapy, DC-CIK therapy could significantly increase the CD3+ T cells, CD3+ CD4+ T cells, and CD4+/CD8+ T cell ratio in NSCLC.